CD19-CD22 CAR-T cells
QT2019005
Phase 1 mab terminated
Quick answer
CD19-CD22 CAR-T cells for Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
- Phase
- Phase 1
- Modality
- mab
- Status
- terminated